The extra burden of infliximab infusions in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2464-2467

  Buisson, Anthony ^a,b,c   Seigne, Anne Laure ^c   D'Huart, Marie Caroline ^c   Bigard, Marc André ^c   Peyrin Biroulet, Laurent ^c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c CHU NANCY BRABOIS   (France)

Author keywords

Cost effectiveness; Extra burden; Inflammatory bowel disease; Infliximab; Quality of life

Indexed keywords

HYDROCORTISONE; INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; CROHN DISEASE; CROSS-SECTIONAL STUDY; DRUG INFUSION; ENTERITIS; FEMALE; HEALTH CARE SYSTEM; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REIMBURSEMENT; TRAVEL; ULCERATIVE COLITIS; WORK SCHEDULE;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; COST OF ILLNESS; CROHN DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HEALTH RESOURCES; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; LENGTH OF STAY; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TRANSPORTATION; YOUNG ADULT;

EID: 84888260022     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182a19268     Document Type: Article

References (21)

1. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohns disease in population-based cohorts. Am J Gastroenterol. 2010;105:289-297.
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohns disease in population-based cohorts. Inflamm Bowel Dis. 2011;17:471-478.
3. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohns disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008;6: 644-653.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787.
6. Sandborn WJ, Van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-265.
7. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Disability in inflammatory bowel diseases: developing ICF Core Sets for patients with inflammatory bowel diseases based on the International Classification of Functioning, Disability, and Health. Inflamm Bowel Dis. 2010;16:15-22.
8. Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut. 2012;61: 241-247.
9. Vavricka SR, Bentele N, Scharl M, et al. Systematic assessment of factors influencing preferences of Crohns disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL). Inflamm Bowel Dis. 2012;18: 1523-1530.
10. Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohns disease. Gut. 2011;60:930-936.
11. Peyrin-Biroulet L, Pillot C, Oussalah A, et al. Urinary tract infections in hospitalized inflammatory bowel disease patients: A 10-year experience. Inflamm Bowel Dis. 2012;18:697-702.
12. Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis. 2012;18:1641-1646.
13. Babouri A, Buisson A, Bigard MA, et al. Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7:129-133.
14. Breynaert C, Ferrante M, Fidder H, et al. Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: A single-center cohort study. Am J Gastroenterol. 2011;106:778-785.
15. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohns disease: special situations. J Crohns Colitis. 2010;4:63-101.
16. Chilton F, Collett RA. Treatment choices, preferences and decisionmaking by patients with rheumatoid arthritis. Musculoskeletal Care. 2008;6:1-14.
17. Filipovic I, Walker D, Forster F, et al. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford). 2011; 50:1083-1090.
18. Strand V, Singh JA. Newer biological agents in rheumatoid arthritis: Impact on health-related quality of life and productivity. Drugs. 2010;70:121-145.
19. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992;14:318-327.
20. Yu AP, Johnson S, Wang ST, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohns disease. Pharmacoeconomics. 2009;27:609-621.
21. Di Sabatino A, Liberato L, Marchetti M, et al. Optimal use and costeffectiveness of biologic therapies in inflammatory bowel disease. Intern Emerg Med. 2011;6(suppl 1):17-27.